Inhibition of melanoma cell directional migration in vitro via different cellular targets. 1993

R Fink-Puches, and C Helige, and H Kerl, and J Smolle, and H A Tritthart
Department of Dermatology and Venerology, University of Graz, Austria.

In malignant melanoma active movement of cancer cells is considered to be essential for tissue invasion. Various mechanisms, such as the Ca(2+)-calmodulin-proteinkinase C cascade or G-protein-dependent processes are considered to play a role in tumor cell functions. The assay of directional migration, combined with computer-assisted image analysis, was used to evaluate the antimigratory efficacy of drugs interfering with different steps of signal transduction pathways. Treatment with different compounds showed a more or less concentration-dependent reduction of migration rates: The Ca(2+)-channel blockers verapamil and devapamil showed a slight reduction of motility. The effect was more pronounced when the calmodulin antagonist flunarizine was used or the proteinkinase C inhibitors dequalinium, tamoxifen and H-7 were applied. A marked inhibition of motility was found with the G-protein antagonist L 651582. Thus, our results indicate that different signal transduction pathways are involved in the regulation of directional migration of K1735-M2 melanoma cells.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011493 Protein Kinase C An serine-threonine protein kinase that requires the presence of physiological concentrations of CALCIUM and membrane PHOSPHOLIPIDS. The additional presence of DIACYLGLYCEROLS markedly increases its sensitivity to both calcium and phospholipids. The sensitivity of the enzyme can also be increased by PHORBOL ESTERS and it is believed that protein kinase C is the receptor protein of tumor-promoting phorbol esters. Calcium Phospholipid-Dependent Protein Kinase,Calcium-Activated Phospholipid-Dependent Kinase,PKC Serine-Threonine Kinase,Phospholipid-Sensitive Calcium-Dependent Protein Kinase,Protein Kinase M,Calcium Activated Phospholipid Dependent Kinase,Calcium Phospholipid Dependent Protein Kinase,PKC Serine Threonine Kinase,Phospholipid Sensitive Calcium Dependent Protein Kinase,Phospholipid-Dependent Kinase, Calcium-Activated,Serine-Threonine Kinase, PKC
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D003868 Dequalinium A topical bacteriostat that is available as various salts. It is used in wound dressings and mouth infections and may also have antifungal action, but may cause skin ulceration. Decamine,Dequadin,Dequalinium Acetate,Dequalinium Chloride,Dequalinium Di-10-undecenoate,Dequalinium Diacetate,Dequalinium Dibromide,Dequalinium Dichloride,Dequalinium Diiodide,Dequalinium Diundecenoate,Dynexan-MHP,Evazol,Fluomycin,Gargilon,Gurgellösung-Ratiopharm,Labosept,Maltyl,Solvidont,Sorot,Acetate, Dequalinium,Chloride, Dequalinium,Di-10-undecenoate, Dequalinium,Diacetate, Dequalinium,Dibromide, Dequalinium,Dichloride, Dequalinium,Diiodide, Dequalinium,Diundecenoate, Dequalinium,Dynexan MHP,Gurgellösung Ratiopharm
D005444 Flunarizine Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. Flunarizin,Flunarizine Dihydrochloride,Flunarizine Hydrochloride,R-14950,Sibelium,Dihydrochloride, Flunarizine,Hydrochloride, Flunarizine,R 14950,R14950
D000620 Aminoimidazole Carboxamide An imidazole derivative which is a metabolite of the antineoplastic agents BIC and DIC. By itself, or as the ribonucleotide, it is used as a condensation agent in the preparation of nucleosides and nucleotides. Compounded with orotic acid, it is used to treat liver diseases. Ba 2756,Carboxamide, Aminoimidazole

Related Publications

R Fink-Puches, and C Helige, and H Kerl, and J Smolle, and H A Tritthart
December 1971, Infection and immunity,
R Fink-Puches, and C Helige, and H Kerl, and J Smolle, and H A Tritthart
August 2003, The Journal of biological chemistry,
R Fink-Puches, and C Helige, and H Kerl, and J Smolle, and H A Tritthart
May 2015, Integrative biology : quantitative biosciences from nano to macro,
R Fink-Puches, and C Helige, and H Kerl, and J Smolle, and H A Tritthart
July 2018, Development (Cambridge, England),
R Fink-Puches, and C Helige, and H Kerl, and J Smolle, and H A Tritthart
June 1980, Clinical and experimental immunology,
R Fink-Puches, and C Helige, and H Kerl, and J Smolle, and H A Tritthart
July 2010, Cell cycle (Georgetown, Tex.),
R Fink-Puches, and C Helige, and H Kerl, and J Smolle, and H A Tritthart
January 1980, The Indian journal of medical research,
R Fink-Puches, and C Helige, and H Kerl, and J Smolle, and H A Tritthart
February 2022, Journal of cell science,
R Fink-Puches, and C Helige, and H Kerl, and J Smolle, and H A Tritthart
May 2014, Soft matter,
R Fink-Puches, and C Helige, and H Kerl, and J Smolle, and H A Tritthart
January 1978, Voprosy onkologii,
Copied contents to your clipboard!